Consistent with the results showing changes in MLANA transcript levels, treatment of MITF-Mhigh melanoma cells with vemurafenib or trametinib for 44 h resulted in increased percentages of Melan-A-positive cells (Figure 4(c)). Here, MLANA is linked to melanoma.